The U.S. Food and Drug Administration approved Eli Lilly and Co.’s once-daily weight-loss Foundayo Pill for adults with obesity or weight-related conditions, offering the first GLP-1 oral treatment without food or water restrictions.
FDA Clears First Flexible Oral GLP-1 Weight-Loss Drug
The FDA approval marks the first glucagon-like peptide-1, or GLP-1, receptor agonist pill designed for chronic weight management that can be taken at any time of day without dietary timing requirements.
Eli Lilly and Co. said prescriptions are accepted immediately through its LillyDirect platform, with shipping scheduled to begin April 6. The drug is expected to become widely available through retail pharmacies and telehealth providers soon after.
Foundayo Pill, known scientifically as orforglipron, is approved for adults with obesity or those who are overweight with related medical conditions when combined with a reduced-calorie diet and increased physical activity.
“People living with obesity need treatment options that meet them where they are,” said Dr. Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston. She said the pill provides flexibility compared with injectable treatments while delivering meaningful weight loss results.
Clinical Trials Show Significant Weight Loss Results
The approval is supported by results from Lilly’s global ATTAIN Phase 3 clinical trial program, which enrolled more than 4,500 participants.
In the ATTAIN-1 study, participants taking the highest dose who remained on treatment lost an average of 27.3 pounds, or 12.4 percent of body weight, compared with 2.2 pounds among those receiving a placebo. Across all participants, regardless of completion, average weight loss reached about 25 pounds.
Researchers also reported improvements in several cardiovascular risk markers, including waist circumference, triglycerides, non-HDL cholesterol, and systolic blood pressure.
David A. Ricks, Lilly’s chair and chief executive officer, said access barriers have limited the use of existing GLP-1 therapies.
“Fewer than one in 10 people who could benefit from a GLP-1 are taking one,” Ricks said. “A convenient, once-daily oral pill delivering meaningful weight loss is obesity care designed for the real world.”
Joe Nadglowski, president and CEO of the Obesity Action Coalition, said expanding treatment options helps patients find approaches suited to individual lifestyles and long-term health goals.
Pricing, Safety Warnings, and Global Expansion Plans
Lilly said eligible commercially insured patients may pay as little as $25 per month using a savings program. Self-pay pricing is expected to begin at $149 per month for the lowest dose. Medicare Part D beneficiaries may qualify for approximately $50 monthly access beginning July 1.
The company cautioned that Foundayo should not be used with other GLP-1 medications and has not been established as safe for children.
Safety warnings include a potential risk of thyroid tumors, including thyroid cancer. Patients are advised to report symptoms such as neck swelling, hoarseness, or difficulty swallowing. Common side effects include nausea, constipation, diarrhea, vomiting, abdominal pain, fatigue, and headache.
Health officials also warned of possible risks, including pancreatitis, dehydration-related kidney problems, low blood sugar when used with certain diabetes drugs, and severe allergic reactions.
Lilly said it has submitted regulatory applications for orforglipron in more than 40 countries for weight management and type 2 diabetes treatment, and plans to launch shortly after approvals are granted.
The company described Foundayo Pill as part of its broader effort to expand access to obesity treatment as demand for GLP-1 therapies continues to rise globally.
